Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4211
Title: Prevalence and subtyping of biofilms present in bronchoalveolar lavage from children with protracted bacterial bronchitis or non-cystic fibrosis bronchiectasis: a cross-sectional study
Authors: Richmond, P.
Chang, Anne 
Clark, S.
Marsh, R. L.
Binks, M. J.
Smith-Vaughan, H. C.
Janka, M.
Thornton, R. B.
Issue Date: 2022
Source: Mar 3, (3), 2022, p. e215-e223
Pages: e215-e223
Journal: Lancet Microbe
Abstract: BACKGROUND: Lower airway biofilms are hypothesised to contribute to poor treatment outcomes among children with chronic lung disease; however, data are scarce. We aimed to determine the presence and prevalence of biofilm in bronchoalveolar lavage from children with protracted bacterial bronchitis (PBB) or bronchiectasis; whether biofilm was associated with signs of lower airway infection; and whether biofilms were consistent with an upper or lower airway origin. METHODS: In this cross-sectional study, fluorescent microscopy techniques were used to detect biofilm in archived bronchoalveolar lavage specimens from a paediatric cohort (age <18 years) with PBB or bronchiectasis who were prospectively recruited to observational studies of chronic cough at Royal Children's Hospital (Brisbane, Australia) or Royal Darwin Hospital (Darwin, Australia). Children with cystic fibrosis were excluded. Lower airway infection was defined as bronchoalveolar lavage neutrophil percentage of 15% or more, or a culture of a bacterial pathogen at 10(4) colony-forming units per mL or more, or both. Biofilms were subtyped as either of lower airway origin (unrelated to squamous epithelial cells) or of upper airway origin (observed in close association with squamous epithelial cells). Bronchoalveolar lavages were considered contaminated with upper airway secretions if the squamous cell proportion was more than ten cells per 1000 nucleated cells (>1%). Primary outcomes were the prevalence of each biofilm subtype among children with PBB compared with children with bronchiectasis. Secondary outcomes were the prevalence of each biofilm subtype among children with signs of lower airway infection compared to children without. FINDINGS: Biofilm testing was performed on 144 bronchoalveolar lavage specimens collected between Jan 1, 2011, and Dec 16, 2014, and preserved at -80°C before biofilm testing (69 children with PBB from Brisbane and 75 children with bronchiectasis from Darwin). The prevalence of lower airway biofilms (unrelated to squamous epithelial cells) was similar among the children with PBB (25 [36%] of 69) and children with bronchiectasis (31 [41%] of 75; odds ratio [OR] 1·24, 95% CI 0·63-2·43), but higher among children with signs of lower airway infection (46 [48%] of 95) than children without (eight [19%] of 43; OR 4·11, 95% CI 1·73-9·78), irrespective of the underlying diagnosis. By contrast, upper airway biofilms (associated with squamous epithelial cells) were more prevalent among children with bronchiectasis (32 [43%] of 75) than children with PBB (16 [23%] of 69; OR 2·47, 95% CI 1·20-5·08) and were unrelated to lower airway infection. Upper airway contamination was uncommon (eight [11%] of 71) and was not evident in 23 (79%) of 29 bronchoalveolar lavages that were positive for upper airway biofilms. INTERPRETATION: Lower airway biofilms are prevalent, but not ubiquitous, in bronchoalveolar lavage from children with PBB or bronchiectasis, suggesting anti-biofilm therapies might be beneficial for some children. Detection of upper airway biofilms in bronchoalveolar lavage that did not have signs of contamination suggests that microaspiration might be important in some children. Specimen quality measures are recommended for future studies to account for the presence of upper airway biofilms. FUNDING: Financial Markets for Children Project Grant, National Health and Medical Research Council of Australia, Rebecca L Cooper Medical Research Foundation, Queensland Children's Hospital Foundation, and BrightSpark Foundation.2666-5247Marsh, Robyn L
Binks, Michael J
Smith-Vaughan, Heidi C
Janka, Maxine
Clark, Sharon
Richmond, Peter
Chang, Anne B
Thornton, Ruth B
Journal Article
Observational Study
England
Lancet Microbe. 2022 Mar;3(3):e215-e223. doi: 10.1016/S2666-5247(21)00300-1. Epub 2022 Feb 1.
DOI: 10.1016/s2666-5247(21)00300-1
Keywords: Prevalence;Humans;*Cystic Fibrosis/complications;Cross-Sectional Studies;Child;Bronchoalveolar Lavage Fluid/microbiology;for an unlicensed vaccine (GSK) and a COVID-19 vaccine for children (Moderna),;Adolescent*Bacterial Infections/complications;Biofilms;*Bronchiectasis/epidemiology;*Bronchitis, Chronic/complications;Bronchoalveolar Lavage;outside the submitted work. RBT reports grants from the Financial Markets for;Children and the BrightSpark Foundation, during the conduct of the study. All;other authors declare no competing interests.;cough (Merck) and for serving as an Independent Data Monitoring Committee member;fees relating to advising the study design for an unlicensed molecule for chronic;and institutional;grants from Financial Markets for Children, during the conduct of the study. ABC;Rebecca L Cooper Foundation during the conduct of this study. HCS-V reports;National Health and Medical Research Council of Australia (NHMRC), and the;reports grants from NHMRC during the conduct of this study
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

66
checked on Feb 13, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.